学科主题临床医学
Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial
Hou, J. L.1,2; Gao, Z. L.3; Xie, Q.4; Zhang, J. M.5; Sheng, J. F.6; Cheng, J.7; Chen, C. W.8; Mao, Q.9; Zhao, W.10; Ren, H.11; Tan, D. M.12; Niu, J. Q.13; Chen, S. J.14; Pan, C.15; Tang, H.16; Wang, H.17; Mao, Y. M.18; Jia, J. D.19; Ning, Q.20; Xu, M.21; Wu, S. M.22; Li, J.23; Zhang, X. X.4; Ji, Y.24; Dong, J.25; Li, J.25
关键词Antiviral Therapy Chronic Hepatitis b Efficacy Tenofovir Disoproxil Fumarate
刊名JOURNAL OF VIRAL HEPATITIS
2015-02-01
DOI10.1111/jvh.12313
22期:2页:85-93
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Gastroenterology & Hepatology ; Infectious Diseases ; Virology
研究领域[WOS]Gastroenterology & Hepatology ; Infectious Diseases ; Virology
关键词[WOS]VIRUS ; LAMIVUDINE ; SUSCEPTIBILITY ; RESISTANCE ; MUTATIONS ; INFECTION ; CIRRHOSIS ; THERAPY ; RISK
英文摘要

Tenofovir disoproxil fumarate (TDF) has demonstrated long-term efficacy and a high barrier to resistance in multiple chronic hepatitis B (CHB) populations outside of China. This study aimed to evaluate the efficacy and safety of TDF compared with adefovir dipivoxil (ADV) in Chinese patients with CHB during 48 weeks of treatment (ClinicalTrial.gov number, NCT01300234). A Phase 3, multicentred, randomized, double-blind, controlled trial compared the efficacy and safety of TDF with ADV in Chinese patients with CHB. The primary endpoint was the proportion of patients with HBV DNA <400 copies/mL in each treatment group at Week 48, using an unpooled Z-test for superiority. Secondary endpoints included viral suppression, serologic response, histological improvement, normalization of alanine aminotransferase (ALT) levels and the emergence of resistance mutations. A total of 509 patients, 202 hepatitis B e antigen (HBeAg)-positive and 307 HBeAg-negative, with HBV DNA >= 10(5) copies/mL received either TDF 300 mg od or ADV 10 mg od. At Week 48, TDF demonstrated superior viral suppression compared with ADV in both HBeAg-positive (76.7% vs 18.2%, P < 0.0001) and HBeAg-negative (96.8% vs 71.2%, P < 0.0001) patients. The majority of patients in both treatment arms achieved ALT normalization (>85%). No resistance to TDF was observed. The frequency of adverse events was comparable between treatment arms (TDF 3.9% vs ADV 4.8%). In this double-blind, randomized, clinical trial, TDF demonstrated superiority over ADV with respect to viral suppression in Chinese patients with CHB at 48 weeks of treatment and without the development of resistance.

语种英语
WOS记录号WOS:000350545800002
资助机构GlaxoSmithKline
引用统计
被引频次:8[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/55796
专题北京大学第二临床医学院_北京大学肝病研究所
北京大学第二临床医学院_肝病科
作者单位1.Ruijin Hosp, Dept Infect Dis, Shanghai, Peoples R China
2.Huashan Hosp, Dept Infect Dis, Shanghai, Peoples R China
3.Nanfang Hosp, Dept Infect Dis, Guangzhou, Guangdong, Peoples R China
4.Nanfang Hosp, Hepatol Unit, Guangzhou, Guangdong, Peoples R China
5.Sun Yat Sen Univ, Affiliated Hosp 3, Dept Infect Dis, Guangzhou 510275, Guangdong, Peoples R China
6.Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Infect Dis, Hangzhou 310003, Zhejiang, Peoples R China
7.Capital Med Univ, Beijing Ditan Hosp, Ctr Liver Dis, Beijing, Peoples R China
8.Nanjing Mil, Hosp 85, Liver Dis Res Ctr, Shanghai, Peoples R China
9.Southwest Hosp, Dept Infect Dis, Chongqing, Peoples R China
10.Second Hosp Nanjing, Dept Liver Dis, Nanjing, Jiangsu, Peoples R China
11.Chongqing Med Univ, Affiliated Hosp 2, Dept Infect Dis, Chongqing, Peoples R China
12.Cent S Univ, Xiangya Hosp, Dept Infect Dis, Changsha, Hunan, Peoples R China
13.Jilin Univ, Affiliated Hosp 1, Dept Hepatol, Changchun 130023, Peoples R China
14.Jinan Hosp Infect Dis, Dept Liver Dis, Jinan, Peoples R China
15.Fuzhou Infect Dis Hosp, Dept Hepatol, Fuzhou, Peoples R China
16.Sichuan Univ, West China Hosp, Ctr Infect Dis, Chengdu 610064, Peoples R China
17.Peking Univ, Peoples Hosp, Inst Hepatol, Beijing 100871, Peoples R China
18.Renji Hosp, Dept Gastroenterol, Shanghai, Peoples R China
19.Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing, Peoples R China
20.Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Infect Dis, Wuhan 430074, Peoples R China
21.Guangzhou 8th Peoples Hosp, Dept Liver Dis, Guangzhou, Guangdong, Peoples R China
22.Shanghai Publ Hlth Clin Ctr, Dept Liver Dis, Shanghai, Peoples R China
23.Zhongshan Hosp, Shanghai, Peoples R China
24.Nanjing Med Univ, Affiliated Hosp 1, Dept Infect Dis, Nanjing, Jiangsu, Peoples R China
25.GlaxoSmithKline R&D China, China Med Dev, Shanghai, Peoples R China
推荐引用方式
GB/T 7714
Hou, J. L.,Gao, Z. L.,Xie, Q.,et al. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial[J]. JOURNAL OF VIRAL HEPATITIS,2015,22(2):85-93.
APA Hou, J. L..,Gao, Z. L..,Xie, Q..,Zhang, J. M..,Sheng, J. F..,...&Li, J..(2015).Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.JOURNAL OF VIRAL HEPATITIS,22(2),85-93.
MLA Hou, J. L.,et al."Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial".JOURNAL OF VIRAL HEPATITIS 22.2(2015):85-93.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Hou, J. L.]的文章
[Gao, Z. L.]的文章
[Xie, Q.]的文章
百度学术
百度学术中相似的文章
[Hou, J. L.]的文章
[Gao, Z. L.]的文章
[Xie, Q.]的文章
必应学术
必应学术中相似的文章
[Hou, J. L.]的文章
[Gao, Z. L.]的文章
[Xie, Q.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。